Institut Pasteur

Centre National De La Recherche Scientifique

Francois Rougeon

Catherine Rougeot

Pierre Lafaye

Jean-Pierre Bourgeois

Isabelle Rosinski-Chupin

Diana Tronik

Nabil Seidah

Sacha Kallenbach

Noelle Doyen

Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications

The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

A process for screening for a ligand molecule that possesses an agonist biological activity on the NEP binding site for an SMR1 peptide, such as the QHNPR (SEQ ID NO: 2) pentapeptide. The method comprises preparing a cell culture or preparing an organ specimen or a tissue sample containing NEP binding sites for an SMR1 peptide, incubating the cell culture, organ specimen or tissue sample of at concentrations allowing measurement of NEP enzymatic activity under initial velocity conditions in the presence of a candidate ligand molecule, a half-saturating concentration of an SMR1 peptide, and a NEP substrate during a time sufficient for the hydrolysis activity of the NEP substrate to take place under initial velocity conditions; and quantifying the activity of the NEP present in the biological material of by measuring the levels of NEP substrate hydrolysis, respectively in the presence or in the absence of the ligand molecule and in the presence or in the absence of the SMR1 peptide.

Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide

The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to the selected ligand molecules themselves.

Therapeutic use of the SMR1 protein and active derivatives thereof

This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder.

Treatment of mood disorders by administration of SMR1

The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist' biological activity on the target receptor of the QHNPR pentapeptide as well as to the selected ligand molecules themselves.

The present invention relates to peptides and polypeptides derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls:

Antibodies directed against peptides derived from the SMR1 polypeptide

The present invention relates to peptides and polypeptides derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formula:

Growing community of inventors

Sevres, France

Francois Rougeon